7 reviews for American Diabetes Association 86th Scientific Sessions – 2026 Update

1. Madelyn Haney

   Rated 4 out of 5

   This program offers valuable coverage, although the sheer number of sessions can feel overwhelming at first. A clearer recommended learning path for p...More

   This program offers valuable coverage, although the sheer number of sessions can feel overwhelming at first. A clearer recommended learning path for primary care, technology, obesity, or complications would make navigation easier. Even so, the content range is a major strength. I found the updates on GLP-1 therapies, CGM, cardiometabolic risk, nutrition, and hypoglycemia particularly relevant. The multidisciplinary approach also helps show how diabetes management intersects with renal, cardiovascular, behavioral, and weight-related concerns. Learners who choose topics based on their immediate needs should find plenty of useful material. It is best approached as a comprehensive reference library rather than a course that must be completed in a single sequence.

   Helpful? 0 0
   Alonso Munoz

   Rated 5 out of 5

   The most useful aspect of this course is the ability to explore different clinical areas without relying on dozens of separate resources. Topics such ...More

   The most useful aspect of this course is the ability to explore different clinical areas without relying on dozens of separate resources. Topics such as diabetic kidney disease, cardiovascular risk, neuropathy, retinopathy, foot care, hypoglycemia, and metabolic liver disease are presented alongside updates in medications and devices. That combination makes the program relevant for clinicians managing patients with multiple complications. I also liked the emphasis on translating research into care strategies, because understanding a trial result is different from deciding how it may fit into real practice. The material is extensive, but it can be approached selectively according to each learner’s specialty, knowledge gaps, or current patient-care priorities.

   Helpful? 0 0
   Eldridge Hale

   Rated 5 out of 5

   his is a strong resource for anyone trying to keep pace with the rapidly changing landscape of obesity and diabetes treatment. The program examines GL...More

   his is a strong resource for anyone trying to keep pace with the rapidly changing landscape of obesity and diabetes treatment. The program examines GLP-1 receptor agonists across different populations, emerging oral agents, combination therapies, body-composition questions, treatment access, and long-term weight-management outcomes. I appreciated that it also includes nutrition, behavior change, mental health, and patient experience rather than presenting medication as the only solution. The clinical topics are supported by broader discussions of research and care delivery, which makes the content relevant to both specialists and multidisciplinary teams. Overall, the program offers a comprehensive way to identify the major questions and developments influencing metabolic care in 2026.

   Helpful? 0 0
   Lenard Bonilla

   Rated 5 out of 5

   I was most interested in the diabetes technology content, and the program delivered a wide range of perspectives. It covers continuous glucose monitor...More

   I was most interested in the diabetes technology content, and the program delivered a wide range of perspectives. It covers continuous glucose monitoring, insulin delivery systems, clinical algorithms, connected data, organizational readiness, and the practical limitations that can affect adoption. The inclusion of AI and real-world data adds another useful layer, especially for clinicians trying to understand where innovation may genuinely improve care and where more evidence is still needed. Beyond technology, the program also explores therapeutics and complications, so the learning experience does not feel one-dimensional. The breadth may require selective viewing, but having so many relevant subjects collected in one place is a major advantage.

   Helpful? 0 0
   Raquel Vargas

   Rated 5 out of 5

   The course does a good job of highlighting why diabetes care can no longer be reduced to glucose control alone. The discussions around heart, kidney, ...More

   The course does a good job of highlighting why diabetes care can no longer be reduced to glucose control alone. The discussions around heart, kidney, liver, obesity, and metabolic health provide useful context for complex patients who do not fit a simple treatment algorithm. I especially liked the attention given to newer GLP-1 approaches, dual agonists, amylin-based therapies, and evolving weight-management strategies. The scientific scope is extensive, yet the topics remain clinically relevant. For endocrinologists, primary care clinicians, nurses, dietitians, and other members of the care team, this could serve as a detailed update and a useful source of ideas for further study and discussion.

   Helpful? 0 0
   Moses Chapman

   Rated 5 out of 5

   What stood out to me was the depth of coverage across both Type 1 and Type 2 diabetes. Many educational programs focus heavily on medications, but thi...More

   What stood out to me was the depth of coverage across both Type 1 and Type 2 diabetes. Many educational programs focus heavily on medications, but this one also addresses technology, nutrition, behavioral support, hypoglycemia prevention, pregnancy, complications, and health equity. The sections on CGM, automated insulin delivery, and AI-enabled care were particularly helpful for understanding how quickly clinical workflows are changing. I found the multidisciplinary perspective valuable because diabetes patients often have overlapping obesity, cardiovascular, renal, and metabolic concerns. This is the kind of resource that can help a busy healthcare professional organize a large amount of new information into a more coherent picture.

   Helpful? 0 0
   Clara Jarvis

   Rated 5 out of 5

   This program presents an impressively broad view of the developments shaping diabetes care in 2026. The strongest part is the way it connects GLP-1 th...More

   This program presents an impressively broad view of the developments shaping diabetes care in 2026. The strongest part is the way it connects GLP-1 therapies, continuous glucose monitoring, obesity management, cardiovascular risk, and kidney health instead of treating each topic in isolation. The material feels especially useful for a clinician who has limited time to search through separate studies and conference summaries. I also appreciated the practical focus on how emerging technology and new therapeutic options may affect everyday decision-making. The volume of content is substantial, but the range makes it a valuable reference for reviewing unfamiliar areas or revisiting important clinical themes at a convenient pace.

   Helpful? 0 0